JOUNI JORMA UITTO
Medical Practice in Gladwyne, PA
License number
Pennsylvania MD037312E
Category
Medicine
Type
Medical Physician and Surgeon
Address
Address
Gladwyne, PA 19035
Professional information
In Vivo And In Vitro Model Of Cutaneous Photoaging
US Patent:
6018098, Jan 25, 2000
Filed:
Dec 23, 1997
Appl. No.:
8/973449
Inventors:
Eric F. Bernstein - Wynnewood PA
Jouni Uitto - Gladwyne PA
Jouni Uitto - Gladwyne PA
Assignee:
Thomas Jefferson University - Philadelphia PA
International Classification:
C12N 1500, C12N 1585, A61K 4900, C12Q 100
US Classification:
800 18
Abstract:
A transgenic mouse capable of expressing a reporter gene regulated by human elastin promoter is provided. Mouse fibroblast cultures derived from this transgenic mouse are also provided. In addition, methods of identifying compounds capable of inhibiting cutaneous photodamage with this transgenic mouse or fibroblast cultures derived from these mice are provided.
In Vivo And In Vitro Model Of Cutaneous Photoaging
US Patent:
5648061, Jul 15, 1997
Filed:
May 24, 1995
Appl. No.:
8/449826
Inventors:
Eric Bernstein - Wynnewood PA
Jouni Uitto - Gladwyne PA
Jouni Uitto - Gladwyne PA
Assignee:
Thomas Jefferson University - Philadelphia PA
International Classification:
A61K 4900, C12Q 102
US Classification:
424 92
Abstract:
A transgenic mouse capable of expressing human elastin promoter is provided. Mouse fibroblast cultures derived from this transgenic mouse are also provided. In addition methods of identifying compounds capable of inhibiting cutaneous photodamage with this transgenic mouse or fibroblast cultures derived from these mice are provided.
Method For Inhibiting Collagen Synthesis By Keloid Fibroblasts
US Patent:
5500409, Mar 19, 1996
Filed:
Mar 17, 1993
Appl. No.:
8/032714
Inventors:
Elaine M. L. Tan - Gladwyne PA
Jouni J. Uitto - Gladwyne PA
Jouni J. Uitto - Gladwyne PA
Assignee:
Thomas Jefferson University - Philadelphia PA
International Classification:
A61K 3818
US Classification:
514 2
Abstract:
A composition for the treatment of skin fibrotic and other cirrhotic diseases comprising an endothelial cell growth factor, either alone or in combination with heparin or a heparin-like compound is provided. Methods for the treatment of skin fibrotic and other cirrhotic diseases and for inhibition of collagen synthesis by skin fibroblasts using an endothelial cell growth factor either alone or in combination with heparin or a heparin-like compound are also provided.